구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Antibody Drug Conjugate Chemotherapeutic |
Overview Company | Pfizer |
Overview Modality | ADC |
Overview Target | CD33 |
Overview Indication | CD33 Positive Acute Myelogenous Leukemia |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Advanced CD276-Targeting Dual-Payload Antibody-Drug Conjugates for Cancer Therapy.. Antibody-drug conjugate (ADC) represents an effective therapeutic strategy for cancer, leveraging a cancer-targeting monoclonal antibody (mAb) linked to a potent payload. In this study, we report novel dual-payload ADCs (DualADC), which harness one antibody to simultaneously deliver chemotherapy and immunotherapy f… |
Clinical Safety signal | Advanced CD276-Targeting Dual-Payload Antibody-Drug Conjugates for Cancer Therapy.. Antibody-drug conjugate (ADC) represents an effective therapeutic strategy for cancer, leveraging a cancer-targeting monoclonal antibody (mAb) linked to a potent payload. In this study, we report novel dual-payload ADCs (DualADC), which harness one antibody to simultaneously deliver chemotherapy and immunotherapy f… |
Clinical Selected reported efficacy | ORR 51% |
Clinical Reported ORR | 51% |
Clinical Result source | ClinicalTrials.gov NCT02631876 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT02631876 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Antibody Drug Conjugate Chemotherapeutic |
Overview Company | Pfizer |
Overview Modality | ADC |
Overview Target | CD33 |
Overview Indication | CD33 Positive Acute Myelogenous Leukemia |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Advanced CD276-Targeting Dual-Payload Antibody-Drug Conjugates for Cancer Therapy.. Antibody-drug conjugate (ADC) represents an effective therapeutic strategy for cancer, leveraging a cancer-targeting monoclonal antibody (mAb) linked to a potent payload. In this study, we report novel dual-payload ADCs (DualADC), which harness one antibody to simultaneously deliver chemotherapy and immunotherapy f… |
Clinical Safety signal | Advanced CD276-Targeting Dual-Payload Antibody-Drug Conjugates for Cancer Therapy.. Antibody-drug conjugate (ADC) represents an effective therapeutic strategy for cancer, leveraging a cancer-targeting monoclonal antibody (mAb) linked to a potent payload. In this study, we report novel dual-payload ADCs (DualADC), which harness one antibody to simultaneously deliver chemotherapy and immunotherapy f… |
Clinical Selected reported efficacy | ORR 51% |
Clinical Reported ORR | 51% |
Clinical Result source | ClinicalTrials.gov NCT02631876 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT02631876 |
추천 비교
추천 비교